Sustained reactivation of mutant p53 drives durable anti-tumor activity across models, including KRAS co-mutant tumorsFMC-220 selectively stabilizes p53 Y220C at lower doses, overcoming key ...

CAMBRIDGE, MA and ROCKVILLE, MD, USA I April 28, 2025 I Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology with ...

In the study, patients with advanced solid tumors must be HLA-A*02:01 positive and harbor a p53 R175H mutation.

May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML CellsNEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ...

CERo Therapeutics has announced that Colorado Blood Cancer Institute’s (CBCI) Sarah Cannon Research Institute (SCRI), US, ...

Elicio Therapeutics, Inc.’s ELTX share price has surged by 9.07%, which has investors questioning if this is right time to sell.

PMV Pharmaceuticals, Inc.’s PMVP share price has surged by 7.83%, which has investors questioning if this is right time to ...

During a live event, Marc S. Hoffmann, MD, discussed outcomes from the SEQUOIA and ELEVATE-TN studies in chronic lymphocytic ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies ...

CRISPR can't target every location in the genome, and it can't fix the thousands of mutations present in diseases like cystic fibrosis," said co-senior author Omar Abudayyeh, Ph.D., an ...

By integrating cutting-edge computational modeling, deep mutational scanning and laboratory validation, scientists have engineered an antibody that restores full potency against multiple potential ...